Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors

US6930114B2 · kind B2 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Ulrich Niewohner · Wermelskirchen, DE
• Jens-Kerim Ergüden · Uerdingen, DE
• Dietmar Flubacher · Glückstadt, DE
• Paul Naab · Bad Reichenhall, DE
• Thorsten-Oliver Repp · Wesseling, DE
• Jurgen Stoltefuss · Haan, DE
• Nils Burkhardt · Velbert, DE
• Andrea Sewing · Broadstairs, GB
• Michael Schauer · Wuppertal, DE
• Karl-Heinz Schlemmer · Wuppertal, DE
• Olaf Weber · Wülfrath, DE
• Stephen Boyer · Fairfield, US
• Mark Miglarese · Phoenix, US
• Marcus Bauser · Berlin, DE

Key dates

• Filing date: Dec 4, 2001
• Grant date: Aug 16, 2005
• Expiry date: Dec 4, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.